Publications

  • Search by Title

  • Search by Date

  • Select a Category

  • Reset
Clinical publications, Eblasakimab | April 18, 2023

Interim analysis results from a Proof-of-Concept study for ASLAN004 in adult moderate-to-severe atopic dermatitis: a double blind, randomized, placebo-controlled study

Karen A. Veverka , Kenneth Kobayashi, Josemund Menezes , Nicola McIntyre, Alison Ward, April Armstrong, Steven Tien Guan Thng, Jonathan I. Silverberg
Winter Clinical Dermatology Conference, January 2022
Clinical publications, Eblasakimab | June 5, 2021

A phase 1, open-label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor

Lawrence Soon-U Lee, Hartina Hajireen, Alison Ward, Carl Firth
SAD poster publication at SID 2021
Farudodstat, Translational work | February 22, 2021

Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models

S.W. Jones, S.L Penman, N.S French, B.K Park, A.E Chadwick.
Toxicology in Vitro (2021), 72, 105096 - 105096